This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Cooper Companies Announces First Quarter 2014 Results

PLEASANTON, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal first quarter ended January 31, 2014.
  • Revenue increased 7% year-over-year to $405.0 million, up 11% in constant currency and excluding the divestiture of Aime. CooperVision (CVI) revenue up 8% to $326.3 million, up 14% in constant currency and excluding the divestiture of Aime. CooperSurgical (CSI) revenue up 0.3% to $78.7 million.  
  • GAAP earnings per share (EPS) and non-GAAP EPS of $1.47, down 3 cents or 2% and up 24 cents or 20% year over year, respectively.

Commenting on the results, Robert S. Weiss, Cooper's president and chief executive officer said, "We are very pleased to report a strong first quarter. CooperVision continued to gain share in all geographies and modalities with silicone hydrogel products showing especially strong growth led by Biofinity®. CooperSurgical also continued to post solid revenue growth in fertility. Our businesses continue to perform well and we remain excited about the future."

First Quarter GAAP Operating Highlights
  • Revenue $405.0 million, up 7% from last year's first quarter, 11% excluding currency and the divestiture of Aime (CVI's rigid gas permeable contact lens and solutions business in Japan, sold effective October 31, 2013).  
  • Gross margin 65% compared with 63% in last year's first quarter. Gross margin was positively impacted by a lower royalty payment on silicone hydrogel lens sales and favorable product mix, partially offset by lower revenue due to currency, primarily the yen.  
  • Operating margin 20% compared with 18% in last year's first quarter. The increase was the result of gross margin improvement and SG&A leverage.   
  • Depreciation $23.9 million, down 1% from last year's first quarter. Amortization $7.5 million, up 2% from last year's first quarter.  
  • Total debt increased $1.1 million from October 31, 2013 to $345.7 million. Interest expense $1.7 million compared with $2.6 million in last year's first quarter.  
  • Cash provided by operations $68.6 million, capital expenditures $61.0 million and insurance recovery of $1.4 million, resulted in free cash flow $9.0 million.   
  • Shares repurchased $50.0 million (396 thousand shares).

First Quarter CooperVision GAAP Operating Highlights
  • Revenue $326.3 million, up 8% from last year's first quarter, 14% in constant currency and excluding the divestiture of Aime.  
  • Revenue by category:  
        Constant Currency
  (In millions) % of CVI Revenue %chg %chg
  1Q14 1Q14 y/y y/y
Toric  $ 101.2 31% 10% 12%
Multifocal  33.7 10% 24% 24%
Single-use sphere  68.8 21% 5% 14%
Non single-use sphere, other  122.6 38% 5% 6%
Total  $ 326.3 100% 8% 11%
  • Revenue by geography:
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   1Q14  1Q14 y/y y/y
Americas  $ 140.7 43% 13% 13%
EMEA  117.9 36% 16% 13%
Asia Pacific  67.7 21% -9% 6%
Total  $ 326.3 100% 8% 11%
  • Selected revenue by material:
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   1Q14  1Q14 y/y y/y
         
Silicone hydrogel  $ 154.2 47% 29% 30%
Proclear®  $ 82.6 25% 9% 12%
  • Gross margin 65% compared with 63% in last year's first quarter. Gross margin was positively impacted by a lower royalty payment on silicone hydrogel lens sales and favorable product mix, partially offset by lower revenue due to currency, primarily the yen.

First Quarter CooperSurgical GAAP Operating Highlights
  • Revenue $78.7 million, up 0.3% from last year's first quarter.  
  • Revenue by category:
  (In millions) % of CSI Revenue %chg
  1Q14 1Q14 y/y
Office and surgical procedures  $ 50.8 65% -6%
Fertility  27.9 35% 15%
Total  $ 78.7 100% 0%
  • Gross margin 63% compared with 64% in last year's first quarter. The decrease was primarily the result of lower margins associated with the fertility business.

2014 Guidance

The Company revises its full year fiscal 2014 guidance. Guidance is summarized as follows:
  FY14 Guidance FY14 Guidance
  Old New
Revenues (In millions)    
Total $ 1,675 -- $1,735 $ 1,685 -- $1,725
CVI $ 1,355 -- $1,395 $ 1,365 -- $1,395
CSI $ 320 -- $340 $ 320 -- $330
EPS    
GAAP $ 6.70 -- $7.00 $ 6.75 -- $7.00
Non-GAAP $ 6.70 -- $7.00 $ 6.75 -- $7.00

Guidance assumes constant currency as of March 6, 2014.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,751.39 +121.12 0.69%
S&P 500 2,108.57 +15.32 0.73%
NASDAQ 5,111.7330 +22.5270 0.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs